Showing posts with label bone marrow. Show all posts
Showing posts with label bone marrow. Show all posts

Tuesday, 7 October 2014

New Technique Allows Scientists to Find Rare Stem Cells within Bone Marrow

New Technique Allows Scientists to Find Rare Stem Cells within Bone Marrow
Tuesday, 07 October 2014

Deep within the bone marrow resides a type of cells known as mesenchymal stem cells (MSCs). These immature cells can differentiate into cells that produce bone, cartilage, fat, or muscle — a trait that scientists have tried to exploit for tissue repair.

MIT and SMART researchers have developed a
way to isolate mesenchymal stem cells based on
physical traits such as stiffness. Credit: Image
courtesy of the researchers. 
In a new study that should make it easier to develop such stem-cell-based therapies, a team of researchers from MIT and the Singapore-MIT Alliance in Research and Technology (SMART) has identified three physical characteristics of MSCs that can distinguish them from other immature cells found in the bone marrow. Based on this information, they plan to create devices that could rapidly isolate MSCs, making it easier to generate enough stem cells to treat patients.

Until now, there has been no good way to separate MSCs from bone marrow cells that have already begun to differentiate into other cell types, but share the same molecules on the cell surface. This may be one reason why research results vary among labs, and why stem-cell treatments now in clinical trials are not as effective as they could be, says Krystyn Van Vliet, an MIT associate professor of materials science and engineering and biological engineering and a senior author of the paper, which appears in the Proceedings of the National Academy of Sciences this week.

"Some of the cells that you're putting in and calling stem cells are producing a beneficial therapeutic outcome, but many of the cells that you're putting in are not," Van Vliet says.

"Our approach provides a way to purify or highly enrich for the stem cells in that population. You can now find the needles in the haystack and use them for human therapy."

Lead authors of the paper are W.C. Lee, a former graduate student at the National University of Singapore and SMART, and Hui Shi, a former SMART postdoc. Other authors are Jongyoon Han, an MIT professor of electrical engineering and biological engineering, SMART researchers Zhiyong Poon, L.M. Nyan, and Tanwi Kaushik, and National University of Singapore faculty members G.V. Shivashankar, J.K.Y. Chan, and C.T. Lim.

Physical markers
MSCs make up only a small percentage of cells in the bone marrow. Other immature cells found there include osteogenic cells, which have already begun the developmental path toward becoming cartilage- or bone-producing cells. Currently, researchers try to isolate MSCs based on protein markers found on the cell surfaces. However, these markers are not specific to MSCs and can also yield other types of immature cells that are more differentiated.

"Conventional cell-surface markers are frequently used to isolate different types of stem cells from the human bone marrow, but they lack sufficient 'resolution' to distinguish between subpopulations of mesenchymal stromal cells with distinct functions," Lee says.

The researchers set out to find biophysical markers for multipotency — the ability to become many different cell types. They first suspected that cell size might be a factor, because foetal bone marrow stem cells, which tend to have a higher percentage of MSCs, are usually small in diameter.

To test this hypothesis, the researchers used a device Han had previously developed to capture circulating tumour cells based on their size. They isolated bone marrow cells based on size and found that while none of the larger cells were multipotent, not all of the smaller cells were multipotent, so size alone cannot be used to distinguish MSCs.

After measuring several other physical traits, the researchers found two that could be combined with size to completely distinguish MSCs from other stem cells: stiffness of the cell, and the degree of fluctuation in the cell's nuclear membrane.

"You don't need more than these three, but you also can't use fewer than these three," Van Vliet says.

"We now have a triplet of characteristics that identifies populations of cells that are going to be multipotent versus populations of cells that are only going to be able to become bone or cartilage cells."

These features appear to correspond to what is already known about stem cells, Van Vliet says. Compared with cells that have already committed to their final fate, immature cells have genetic material that moves around inside the nucleus, producing more fluctuations of the nuclear cell membrane. Stem cells also have a less rigid cytoskeletal structure than those of highly differentiated cells, at least when adhered to materials such as glass, making those attached cells seem less stiff.

Better regeneration
The researchers then tested the regenerative abilities of the isolated MSCs in mice. They found that these cells could help repair both muscle and bone injuries, while cells identified as osteogenic stromal cells were able to repair bone but not muscle.

"We have provided the first demonstration that subpopulations of mesenchymal stromal cells can be identified and highly enriched for bone growth and muscle repair," Lee says.

"We envision that this approach would also be important in the selection and purification of bone marrow-derived stem cells for tissue repair in human patients suffering from a range of tissue-degenerative diseases."

The team is now working on high-speed methods for separating MSCs. Creating more pure populations of such cells should lead to more effective stem-cell treatments for tissue injuries, Van Vliet says.

"Instead of putting in 30 percent of the cells that you want, and 70 percent filler, you're putting in 100 percent of the cells that you want," she explains.

"That should lead to more reliable patient outcomes, because you're not going to have this variability from batch to batch, or patient to patient, in how many of each cell population are present."

Van Vliet and Poon also hope to begin a clinical trial of the osteogenic cells isolated in this study, which could prove useful for treating bone injuries.

Contact: Sarah McDonnell
.........


For more on stem cells and cloning, go to CellNEWS at

Saturday, 9 August 2014

Stem Cells Show Promise for Stroke Treatment in Pilot Study

Stem Cells Show Promise for Stroke Treatment in Pilot Study
Saturday, 09 August 2014

A stroke therapy using stem cells extracted from patients' bone marrow has shown promising results in the first trial of its kind in humans.

Five patients received the treatment in a pilot study conducted by doctors at Imperial College Healthcare NHS Trust and scientists at Imperial College London.

The therapy was found to be safe, and all the patients showed improvements in clinical measures of disability.

The findings are published in the journal Stem Cells Translational Medicine. It is the first UK human trial of a stem cell treatment for acute stroke to be published.

The therapy uses a type of cell called CD34+ cells, a set of stem cells in the bone marrow that give rise to blood cells and blood vessel lining cells. Previous research has shown that treatment using these cells can significantly improve recovery from stroke in animals. Rather than developing into brain cells themselves, the cells are thought to release chemicals that trigger the growth of new brain tissue and new blood vessels in the area damaged by stroke.

The patients were treated within seven days of a severe stroke, in contrast to several other stem cell trials, most of which have treated patients after six months or later. The Imperial researchers believe early treatment may improve the chances of a better recovery.

A bone marrow sample was taken from each patient. The CD34+ cells were isolated from the sample and then infused into an artery that supplies the brain. No previous trial has selectively used CD34+ cells, so early after the stroke, until now.

Although the trial was mainly designed to assess the safety and tolerability of the treatment, the patients all showed improvements in their condition in clinical tests over a six-month follow-up period.

Four out of five patients had the most severe type of stroke: only four per cent of people who experience this kind of stroke are expected to be alive and independent six months later. In the trial, all four of these patients were alive and three were independent after six months.

Dr Soma Banerjee, a lead author and Consultant in Stroke Medicine at Imperial College Healthcare NHS Trust, said:
"This study showed that the treatment appears to be safe and that it's feasible to treat patients early when they might be more likely to benefit. The improvements we saw in these patients are very encouraging, but it's too early to draw definitive conclusions about the effectiveness of the therapy. We need to do more tests to work out the best dose and timescale for treatment before starting larger trials."

Over 150,000 people have a stroke in England every year. Survivors can be affected by a wide range of mental and physical symptoms, and many never recover their independence.

Stem cell therapy is seen as an exciting new potential avenue of treatment for stroke, but its exact role is yet to be clearly defined.

Dr Paul Bentley, also a lead author of the study, from the Department of Medicine at Imperial College London, said:
"This is the first trial to isolate stem cells from human bone marrow and inject them directly into the damaged brain area using keyhole techniques. Our group are currently looking at new brain scanning techniques to monitor the effects of cells once they have been injected."

Professor Nagy Habib, Principal Investigator of the study, from the Department of Surgery and Cancer at Imperial College London, said:
"These are early but exciting data worth pursuing. Scientific evidence from our lab further supports the clinical findings and our aim is to develop a drug, based on the factors secreted by stem cells, which could be stored in the hospital pharmacy so that it is administered to the patient immediately following the diagnosis of stroke in the emergency room. This may diminish the minimum time to therapy and therefore optimise outcome. Now the hard work starts to raise funds for this exciting research."

Contact: Sam Wong

Reference:
Intra-arterial immunoselected CD34+ stem cells for acute ischemic stroke
Soma Banerjee, Paul Bentley, Mohammad Hamady, Stephen Marley, John Davis, Abdul Shlebak, Joanna Nicholls, Deborah A. Williamson, Steen L. Jensen, Myrtle Gordon, Nagy Habib, Jeremy Chataway
Stem Cells Translational Medicine, 2014;3:1-9. http://dx.doi.org/10.5966/sctm.2013-0178
.........


For more on stem cells and cloning, go to CellNEWS at

Tuesday, 17 June 2014

Embryonic Stem Cells Offer New Treatment for Multiple Sclerosis

Embryonic Stem Cells Offer New Treatment for Multiple Sclerosis
Monday, 16 June 2014

Scientists in the University of Connecticut's Technology Incubation Program have identified a novel approach to treating multiple sclerosis (MS) using human embryonic stem cells, offering a promising new therapy for more than 2.3 million people suffering from the debilitating disease.

The researchers demonstrated that the embryonic stem cell therapy significantly reduced MS disease severity in animal models and offered better treatment results than stem cells derived from human adult bone marrow.

ImStem Biotechnology’s Xiaofang Wang,
seated, and Ren-He Xu. Credit: Tina
Encarnacion/UConn Health Photo.
The study was led by ImStem Biotechnology Inc. of Farmington, Conn., in conjunction with UConn Health Professor Joel Pachter, Assistant Professor Stephen Crocker, and Advanced Cell Technology (ACT) Inc. of Massachusetts. ImStem was founded in 2012 by UConn doctors Xiaofang Wang and Ren-He Xu, along with Yale University doctor Xinghua Pan and investor Michael Men.

"The cutting-edge work by ImStem, our first spinoff company, demonstrates the success of Connecticut's Stem Cell and Regenerative Medicine funding program in moving stem cells from bench to bedside," says Professor Marc Lalande, director of the UConn's Stem Cell Institute.

The research was supported by a $1.13 million group grant from the state of Connecticut's Stem Cell Research Program that was awarded to ImStem and Professor Pachter's lab.

"Connecticut's investment in stem cells, especially human embryonic stem cells, continues to position our state as a leader in biomedical research," says Gov. Dannel P. Malloy.

"This new study moves us one step closer to a stem cell-based clinical product that could improve people's lives."

The researchers compared eight lines of adult bone marrow stem cells to four lines of human embryonic stem cells. All of the bone marrow-related stem cells expressed high levels of a protein molecule called a cytokine that stimulates autoimmunity and can worsen the disease. All of the human embryonic stem cell-related lines expressed little of the inflammatory cytokine.

Another advantage of human embryonic stem cells is that they can be propagated indefinitely in lab cultures and provide an unlimited source of high quality mesenchymal stem cells – the kind of stem cell needed for treatment of MS, the researchers say. This ability to reliably grow high quality mesenchymal stem cells from embryonic stem cells represents an advantage over adult bone marrow stem cells, which must be obtained from a limited supply of healthy donors and are of more variable quality.

"Ground-breaking research like this furthering opportunities for technology ventures demonstrates how the University acts as an economic engine for the state and regional economy," says Jeff Seemann, UConn's vice president for research.

The findings also offer potential therapy for other autoimmune diseases such as inflammatory bowel disease, rheumatoid arthritis, and type-1 diabetes, according to Xu, a corresponding author on the study and one of the few scientists in the world to have generated new human embryonic stem cell lines.

There is no cure for MS, a chronic neuroinflammatory disease in which the body's immune system eats away at the protective sheath called myelin that covers the nerves. Damage to myelin interferes with communication between the brain, spinal cord, and other areas of the body. Current MS treatments only offer pain relief, and slow the progression of the disease by suppressing inflammation.

"The beauty of this new type of mesenchymal stem cells is their remarkable higher efficacy in the MS model," says Wang, chief technology officer of ImStem.

The group's findings appear in the current online edition of Stem Cell Reports, the official journal of the International Society for Stem Cell Research. ImStem is currently seeking FDA approval necessary to make this treatment available to patients.

Contact: Colin Poitras
.........


For more on stem cells and cloning, go to CellNEWS at

Thursday, 5 September 2013

Neuronal-like Cell Differentiation of Non-adherent BMSCs

Neuronal-like Cell Differentiation of Non-adherent BMSCs
Thursday, 05 September 2013

Cells co-labeled with both β-galactosidase and
NeuN were seen in ischemia brain following
transplantation of non-adherent bone marrow
cell-derived mesenchymal stem cells from
β-galactosidase transgenic mice (immunohisto-
chemical staining, ×1000). Credit: Neural
Regeneration Research.
It is widely believed that bone marrow mesenchymal stem cells are highly adherent fibroblastic cells, defined as colony-forming unit-fibroblasts. Nevertheless, a few reports have shown that the non-adherent bone marrow cells can give rise to colony-forming unit-fibroblasts in vitro, and possess a certain differentiation potential.

According to a recent study from Dr. Xiaoming Ben and colleagues, non-adherent bone marrow cell-derived mesenchymal stem cells from C57BL/6J mice cultured using the "pour-off" method developed colony-forming unit-fibroblasts, and could be expanded by supplementation with epidermal growth factor. The non-adherent bone marrow cell-derived mesenchymal stem cells exposed to basic fibroblast growth factor/epidermal growth factor/nerve growth factor expressed the neuron specific markers, neurofilament-200 and NeuN, in vitro.

Non-adherent bone marrow cell-derived mesenchymal stem cells from β-galactosidase transgenic mice were also transplanted into focal ischemic brain (right corpus striatum) of C57BL/6J mice. Cells co-labeled with both β-galactosidase and NeuN were seen by double immunohistochemical staining. These findings, published in the Neural Regeneration Research, suggest that the non-adherent bone marrow cell-derived mesenchymal stem cells could differentiate into neuronal-like cells in vitro and in vivo, which can be used as seed cells for the treatment of nervous system diseases.

Contact: Meng Zhao

Reference:
Neuronal-like cell differentiation of non-adherent bone marrow cell-derived mesenchymal stem cells
Yuxin Wu, Jinghan Zhang, Xiaoming Ben
Neural Regen Res. 2013, 8(22): 2078-2085
.........


For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/

Tuesday, 23 April 2013

Scientists Find Antibody that Transforms Bone Marrow Stem Cells Directly into Brain Cells

Scientists Find Antibody that Transforms Bone Marrow Stem Cells Directly into Brain Cells

Tuesday, 23 April 2013

In a serendipitous discovery, scientists at The Scripps Research Institute (TSRI) have found a way to turn bone marrow stem cells directly into brain cells.

Current techniques for turning patients' marrow cells into cells of some other desired type are relatively cumbersome, risky and effectively confined to the lab dish. The new finding points to the possibility of simpler and safer techniques. Cell therapies derived from patients' own cells are widely expected to be useful in treating spinal cord injuries, strokes and other conditions throughout the body, with little or no risk of immune rejection.

Scientists at the Scripps Research Institute
have found a simple way to turn bone marrow
stem cells directly into brain precursor cells,
such as those shown here. Credit: Image
courtesy of the Lerner lab, The Scripps Research
Institute. 
"These results highlight the potential of antibodies as versatile manipulators of cellular functions," said Richard A. Lerner, the Lita Annenberg Hazen Professor of Immunochemistry and institute professor in the Department of Cell and Molecular Biology at TSRI, and principal investigator for the new study.

"This is a far cry from the way antibodies used to be thought of — as molecules that were selected simply for binding and not function."

The researchers discovered the method, reported in the online Early Edition of the Proceedings of the National Academy of Sciences the week of April 22, 2013, while looking for lab-grown antibodies that can activate a growth-stimulating receptor on bone marrow cells. One antibody turned out to activate the receptor in a way that induces marrow stem cells — which normally develop into white blood cells — to become neural progenitor cells, a type of almost-mature brain cell.

Nature's Toolkit
Natural antibodies are large, Y-shaped proteins produced by immune cells. Collectively, they are diverse enough to recognize about 100 billion distinct shapes on viruses, bacteria and other targets. Since the 1980s, molecular biologists have known how to produce antibodies in cell cultures in the laboratory. That has allowed them to start using this vast, target-gripping toolkit to make scientific probes, as well as diagnostics and therapies for cancer, arthritis, transplant rejection, viral infections and other diseases.

In the late 1980s, Lerner and his TSRI colleagues helped invent the first techniques for generating large "libraries" of distinct antibodies and swiftly determining which of these could bind to a desired target. The anti-inflammatory antibody Humira®, now one of the world's top-selling drugs, was discovered with the benefit of this technology.

Hongkai Zhang, research associate in the
Lerner lab, which discovered a method for
rapidly finding antibodies that have a desired
effect on cells, not just a desired ability to
bind to a target. Credit: Photo by Cindy
Brauer. 
Last year, in a study spearheaded by TSRI Research Associate Hongkai Zhang, Lerner's laboratory devised a new antibody-discovery technique — in which antibodies is produced in mammalian cells along with receptors or other target molecules of interest. The technique enables researchers to determine rapidly not just which antibodies in a library bind to a given receptor, for example, but also which ones activate the receptor and thereby alter cell function.

Lab Dish in a Cell
For the new study, Lerner laboratory Research Associate Jia Xie and colleagues modified the new technique so that antibody proteins produced in a given cell are physically anchored to the cell's outer membrane, near its target receptors.

"Confining an antibody's activity to the cell in which it is produced effectively allows us to use larger antibody libraries and to screen these antibodies more quickly for a specific activity," said Xie. With the improved technique, scientists can sift through a library of tens of millions of antibodies in a few days.

In an early test, Xie used the new method to screen for antibodies that could activate the GCSF receptor, a growth-factor receptor found on bone marrow cells and other cell types. GCSF-mimicking drugs were among the first biotech bestsellers because of their ability to stimulate white blood cell growth — which counteracts the marrow-suppressing side effect of cancer chemotherapy.

The team soon isolated one antibody type or "clone" that could activate the GCSF receptor and stimulate growth in test cells. The researchers then tested an unanchored, soluble version of this antibody on cultures of bone marrow stem cells from human volunteers. Whereas the GCSF protein, as expected, stimulated such stem cells to proliferate and start maturing towards adult white blood cells, the GCSF-mimicking antibody had a markedly different effect.

"The cells proliferated, but also started becoming long and thin and attaching to the bottom of the dish," remembered Xie.

To Lerner, the cells were reminiscent of neural progenitor cells — which further tests for neural cell markers confirmed they were.

A New Direction
Changing cells of marrow lineage into cells of neural lineage — a direct identity switch termed "transdifferentiation" — just by activating a single receptor is a noteworthy achievement. Scientists do have methods for turning marrow stem cells into other adult cell types, but these methods typically require a radical and risky deprogramming of marrow cells to an embryonic-like stem-cell state, followed by a complex series of molecular nudges toward a given adult cell fate. Relatively few laboratories have reported direct transdifferentiation techniques.

"As far as I know, no one has ever achieved transdifferentiation by using a single protein — a protein that potentially could be used as a therapeutic," said Lerner.

Current cell-therapy methods typically assume that a patient's cells will be harvested, then reprogrammed and multiplied in a lab dish before being re-introduced into the patient. In principle, according to Lerner, an antibody such as the one they have discovered could be injected directly into the bloodstream of a sick patient. From the bloodstream it would find its way to the marrow, and, for example, convert some marrow stem cells into neural progenitor cells.

"Those neural progenitors would infiltrate the brain, find areas of damage and help repair them," he said.

While the researchers still aren't sure why the new antibody has such an odd effect on the GCSF receptor, they suspect it binds the receptor for longer than the natural GCSF protein can achieve, and this lengthier interaction alters the receptor's signalling pattern. Drug-development researchers are increasingly recognizing that subtle differences in the way a cell-surface receptor is bound and activated can result in very different biological effects. That adds complexity to their task, but in principle expands the scope of what they can achieve.

"If you can use the same receptor in different ways, then the potential of the genome is bigger," said Lerner.

Contact: Mika Ono

Reference:
Autocrine signaling based selection of combinatorial antibodies that transdifferentiate human stem cells
Jia Xie, Hongkai Zhang, Kyungmoo Yea, and Richard A. Lerner
PNAS April 23, 2013, doi:10.1073/pnas.1306263110 
.........


For more on stem cells and cloning, go to CellNEWS at

Monday, 4 February 2013

Epidermal Growth Factor Aids Stem Cell Regeneration after Radiation Damage

Epidermal Growth Factor Aids Stem Cell Regeneration after Radiation Damage

Monday, 04 February 2013

Epidermal growth factor has been found to speed the recovery of blood-making stem cells after exposure to radiation, according to Duke Medicine researchers. The finding could open new options for treating cancer patients and victims of dirty bombs or nuclear disasters.

Reported in the Feb. 3, 2013, issue of the journal Nature Medicine, the researchers explored what had first appeared to be an anomaly among certain genetically modified mice with an abundance of epidermal growth factor in their bone marrow. The mice were protected from radiation damage, and the researchers questioned how this occurred.

"Epidermal growth factor was not known to stimulate hematopoiesis, which is the formation of blood components derived from hematopoietic stem cells," said senior author John Chute, M.D., a professor of medicine and professor of pharmacology and cancer biology at Duke University.

"However, our studies demonstrate that the epidermal growth promotes hematopoietic stem cell growth and regeneration after injury."

Hematopoietic stem cells, which constantly churn out new blood and immune cells, are highly sensitive to radiation damage. Protecting these cells or improving their regeneration after injury could benefit patients who are undergoing bone marrow transplantation, plus others who suffer radiation injury from accidental environmental exposures such as the Japanese nuclear disaster in 2011.

The Duke researchers launched their investigation using mice specially bred with deletions of two genes that regulate the death of endothelial cells, which line the inner surface of blood vessels and are thought to regulate the fate of hematopoietic stem cells. Blood vessels and the hematopoietic system in these mice were less damaged when exposed to high doses of radiation, improving their survival.

An analysis of secretions from bone marrow endothelial cells of the protected mice showed that epidermal growth factor (EGF) was significantly elevated - up to 18-fold higher than what was found in the serum of control mice. The researchers then tested whether EGF could directly spur the growth of stem cells in irradiated bone marrow cultured in the lab. It did, with significant recovery of stem cells capable of repopulating transplanted mice.

Next, the Duke team tried the approach in mice using three different solutions of cells in animals undergoing bone marrow transplants. One group received regular bone marrow cells; a second group got bone marrow cells from donors that had been irradiated and treated with EGF; a third group got bone marrow cells from irradiated donors treated with saline.

The regular bone marrow cells proliferated well and had the highest rate of engraftment in the recipient mice. But mice that were transplanted with the cells from irradiated/EGF-treated donors had 20-fold higher engraftment rate than the third group.

Additional studies showed that EGF improved survival from a lethal radiation exposure, with 93 percent of mice surviving the radiation dose if they subsequently received treatment with EGF, compared to 53 percent surviving after treatment with a saline solution.

Chute said it appears that EGF works by repressing a protein called PUMA that normally triggers stem cell death following radiation exposure.

"We are just beginning to understand the mechanisms through which EGF promotes stem cell regeneration after radiation injury," Chute said.

"This study suggests that EGF might have potential to accelerate the recovery of the blood system in patients treated with chemotherapy or radiation."

Contact: Sarah Avery

Reference:
Epidermal growth factor regulates hematopoietic regeneration after radiation injury
Phuong L Doan, Heather A Himburg, Katherine Helms, J Lauren Russell, Emma Fixsen, Mamle Quarmyne, Jeffrey R Harris, Divino Deoliviera, Julie M Sullivan, Nelson J Chao, David G Kirsch & John P Chute
Nature Medicine, 03 February 2013, doi:10.1038/nm.3070
.........


For more on stem cells and cloning, go to CellNEWS at

Tuesday, 20 December 2011

Bone Marrow-derived Cells Differentiate in the Brain through Mechanisms of Plasticity

Bone Marrow-derived Cells Differentiate in the Brain through Mechanisms of Plasticity
Monday, 19 December 2011

Bone marrow-derived stem cells (BMDCs) have been recognized as a source for transplantation because they can contribute to different cell populations in a variety of organs under both normal and pathological conditions. Many BMDC studies have been aimed at repairing damaged brain tissue or helping to restore lost neural function, with much research focused on BMDC transplants to the cerebellum at the back of the brain. In a recent study, a research team from Spain has found that BMDCs, can contribute to a variety of neural cell types in other areas of the brain as well, including the olfactory bulb, because of a mechanism of "plasticity".

Their results are published in the current issue of Cell Transplantation (20:8).

"To our knowledge, ours is the first work reporting the BMDC's contribution to the olfactory neurons," said study corresponding author Dr. Eduardo Weruaga of the University of Salamanca, Spain.

"We have shown for the first time how BMDCs contribute to the central nervous system in different ways in the same animal depending on the region and cell-specific factors."

In this study, researchers grafted bone marrow cells into mutant mice suffering from the degeneration of specific neuronal populations at different ages, then compared them to similarly transplanted healthy controls. An increase in the number of BMDCs was found along the lifespan in both experimental groups. Six weeks after transplantation, however, more bone marrow-derived microglial cells were observed in the olfactory bulbs of the test animals where the degeneration of mitral cells was still in progress. The difference was not observed in the cerebellum where cell degeneration had been completed.

"Our findings demonstrate that the degree of neurodegenerative environment can foster the recruitment of neural elements derived from bone marrow," explained Dr. Weruaga.

"But we also have provided the first evidence that BMDCs can contribute simultaneously to different encephalic areas through different mechanisms of plasticity – cell fusion for Purkinje cells - among the largest and most elaborately dendritic neurons in the human brain – and differentiation for olfactory bulb interneurons."

Dr. Weruaga noted that they confirmed that BMDCs fuse with Purkinje cells but, unexpectedly, they found that the neurodegenerative environment had no effect on the behavior of the BMDCs.

"Interestingly, the contribution of BMDCs occurred through these two different plasticity mechanisms, which strongly suggests that plasticity mechanisms may be modulated by region and cell type-specific factors," he said.

"This study shows a potential new contribution of bone marrow derived cells following transplantation into the brain, making these cells highly versatile, in their ability to both differentiate into and fuse with endogenous neurons" said Dr. Paul R. Sanberg , coeditor-in-chief of Cell Transplantation and distinguished professor of Neuroscience at the Center of Excellence for Aging and Brain Repair, University of South Florida.

Source: Cell Transplantation Center of Excellence for Aging and Brain Repair
Contact: David Eve

Reference:
Bone Marrow Contributes Simultaneously to Different Neural Types in the Central Nervous System Through Different Mechanisms of Plasticity
Recio, J. S.; Álvarez-Dolado, M.; Díaz, D.; Baltanás, F. C.; Piquer-Gil, M.; Alonso, J. R.; Werunga, E.
Cell Transplant. 20(8):1179-1192; 2011
.........
 
ZenMaster

For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/

Sunday, 20 November 2011

Recipient's Immune System Governs Stem Cell Regeneration

Controlling a stem cell transplant recipient’s immune response may be major key to successful bone regeneration   
Sunday, 20 November 2011

A new study in Nature Medicine describes how different types of immune system T-cells alternately discourage and encourage stem cells to regrow bone and tissue, bringing into sharp focus the importance of the transplant recipient's immune system in stem cell regeneration.

The study, conducted at the Center for Craniofacial Molecular Biology at the Ostrow School of Dentistry of USC, examined how mice with genetic bone defects responded to infusions of bone marrow mesenchymal stem cells, or BMMSC.

Under normal conditions, the mice's T-cells produced an inflammatory response and triggered the creation of cellular proteins interferon (INF)-g and tumor necrosis factor (TNF)-a. These attacked and killed the stem cells, preventing the production of new bone.

"Normally, T-cells protect us from infection," said Professor Songtao Shi, corresponding author for the study, "but they can block healthy regeneration from happening."

However, when the mice were given infusions of regulatory T-cells, or Treg, the levels of the interfering INF- g and TNF- a decreased, increasing the rate of bone growth and defect repair. Furthermore, administering the anti-inflammatory drug aspirin at the site of the bone defect also increased the rate at which the BMMSCs were able to regrow bone.

Postdoctoral Research Associate and lead author Yi Liu said the findings illustrate the previously unrecognized role of T-cells in tissue regeneration. They also highlight the need for scientists exploring the possibilities of stem cell regeneration to shift their focus to the immune system, she added.

"Based on what we've found, this should be the direction of more research in the future," Liu said.

Contact: Beth Dunham

Reference:
Mesenchymal stem cell–based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α
Yi Liu, Lei Wang, Takashi Kikuiri, Kentaro Akiyama, Chider Chen, Xingtian Xu, Ruili Yang, WanJun Chen, Songlin Wang, and Songtao Shi
Nature Medicine doi: 10.1038/nm.2542
.........



For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/

Tuesday, 15 November 2011

Stem Cell Study Helps Clarify the Best Time for Therapy to Aid Heart Attack Survivors

Stem Cell Study Helps Clarify the Best Time for Therapy to Aid Heart Attack Survivors
Tuesday, 15 November 2011

A research network led by a Mayo Clinic physician found that stem cells obtained from bone marrow delivered two to three weeks after a person has a heart attack did not improve heart function. This is the first study to systematically examine the timing and method of stem cell delivery and provides vital information for the field of cell therapy.

The results were presented this morning at the 2011 Scientific Sessions of the American Heart Association Meeting in Orlando, Fla. They also will be published online in JAMA to coincide with the presentation.

"Some data suggests that stem cell therapy is helpful within the first week after a heart attack," says Robert Simari, M.D., cardiologist at Mayo Clinic and chairman of the Cardiovascular Cell Therapy Research Network (CCTRN). The network includes five clinics and other sites supported by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health.

"Our study helps identify the limits of when stem cell therapy might be beneficial. We now know that this therapy should not be extended two to three weeks after a heart attack. While it is safe to do so, we did not find any benefit to heart function after six months."

Between July 2008 and February 2011, 87 people with heart attacks and moderate to severe left ventricular dysfunction received their own bone marrow mononuclear stem cells (BMCs) or placebo. The study, called LateTIME, developed a standardized method of processing the BMCs and was the first such trial to provide a uniform dose to each participant.

The researchers assessed heart function through a cardiac MRI by measuring the ejection fraction, or what percentage of blood is pumped out of the left ventricle during each contraction. No significant differences were found in the cardiac function readings between baseline and six months in the BMC group (from 48.7 percent to 49.2 percent) or the placebo group (from 45.3 percent to 48.8 percent).

Dr. Simari says that earlier studies suggest patients with severe heart attacks benefit most from stem cell therapy. The researchers were interested in studying the two- to three-week period because many people who have severe heart attacks are not well enough or stable enough to receive cells right after their heart attacks.

"Many are on life support or other systems, and we didn't think that studying them that early was the best way to assess the benefits to the sickest patients," Dr. Simari says.

The LateTIME study offers a cautionary lesson for people who have had heart attacks and are considering going overseas to seek stem cell treatment.

"We would suggest that individuals not seek treatment outside of the U.S. for therapies that aren't proven effective," Dr. Simari says. The researchers think that the heart may be less receptive to such therapies two to three weeks after a heart attack, or that a person's stem cells are less potent at that time.

Jay Traverse, M.D., lead author of the study and a cardiologist at the Minneapolis Heart Institute at Abbott Northwestern Hospital, says patients will be followed clinically for two years in the LateTIME study.

"There may still be other benefits to stem cell therapy that may be uncovered over time," Dr. Traverse says.

"We observed that patients who received the cell therapy had fewer adverse events such as placement of defibrillators or repeat revascularization compared to patients who got the placebo, consistent with observations in some of the European trials. This therapy may provide hidden safety measures that reduce adverse events and that's something we will follow closely."

LateTIME is one of three heart stem cell trials being conducted by CCTRN. The other trials will explore the effectiveness of stem cell therapy delivered at three days and seven days following a heart attack, and the usefulness of stem cell therapy in people with chronic heart failure.

Source: Mayo Clinic
Contact: Traci Klein
.........



For more on stem cells and cloning, go to CellNEWS at

http://cellnews-blog.blogspot.com/

Delayed Stem Cell Therapy Following Heart Attack is Safe but Not Effective

NIH-funded trial shows that therapy with bone-marrow derived cells does not improve heart function after six months; Future clinical benefits still possible 
Tuesday, 15 November 2011

Stem cells obtained from bone marrow, known as BMCs, can be safely injected into people 2-3 weeks following a heart attack, reports a new clinical trial supported by the National, Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. However, while safe, the BMCs did not improve heart function six months after their administration.

This study, called LateTIME (Transplantation in Myocardial Infarction Evaluation), is the first trial to rigorously examine the safety and potential benefits of extending the timing of stem cell delivery to 2-3 weeks following a heart attack. The results will be presented Monday, Nov. 14, at the 2011 Scientific Sessions of the American Heart Association Meeting in Orlando, Fla. They will also appear online in the Journal of the American Medical Association.

"Although treatment and survival following a heart attack have improved over the years, the risk of heart failure following a heart attack has not decreased," said Susan B. Shurin, M.D., acting director of the NHLBI.

"Stem cell therapy is a promising direction for repairing the damage done by a heart attack. We do not fully understand the optimal use of these cells; studies like LateTIME will help us understand how to perform and monitor these procedures.''

Previous studies have suggested that injecting BMCs into the heart could improve cardiac function following a heart attack and perhaps reduce the need for future hospitalizations and heart surgeries. In contrast to LateTIME, earlier studies delivered BMCs within a few days of the heart attack. In many cases, a patient will not be able to get such immediate treatment, due to poor health following a heart attack or because the hospital providing care doesn't have a stem cell therapy program.

Between July 2008 and February 2011, LateTIME enrolled 87 people with heart attacks who had undergone cardiac procedures to open blocked arteries. The participants all had moderate to severe impairment in their left ventricle, which pumps oxygen-rich blood to the body. All the participants had stem cells taken from bone marrow in their hip for processing. LateTIME researchers developed a standardized method of processing and purifying these stem cells, and this was the first BMC trial to provide a uniform dose of BMCs to each participant. The study then randomly assigned the participants to receive either their purified BMCs or inactive (placebo) cells.

After six months, improvement of heart function was assessed by measuring the percentage of blood that gets pumped out of the left ventricle during each contraction (left-ventricular ejection fraction, or LVEF) by cardiac MRI. There were no significant differences between the change in LVEF readings between baseline and six months in the BMC (from 48.7 percent to 49.2 percent) or placebo (from 45.3 percent to 48.8 percent) groups.

"This does not mean that stem cell therapy will only work if done immediately following a heart attack or that later beneficial effects on clinical outcomes won't emerge," noted Lemuel A. Moyé, M.D., Ph.D., professor of biostatistics at the University of Texas School of Public Health, Houston, and a LateTIME researcher.

"Many factors influence how the heart responds to stem cells, which highlights the critical need to continue rigorous tracking studies in this area."

Moyé added that the health of the study participants will continue to be evaluated for two years, so the BMC therapy may yet demonstrate health benefits such as a lower risk of subsequent heart attacks or heart failure, in which the heart cannot pump enough blood to meet the body's needs.

LateTIME is one of three heart stem cell trials being undertaken by the NHLBI-sponsored Cardiovascular Cell Therapy Research Network. The other trials under way by this multicentre consortium are TIME, which is comparing the effectiveness of stem cell therapy delivered at three days versus seven days following a heart attack, and FOCUS, which is examining stem cell therapy in people with chronic heart failure.

Contact: NHLBI Communications
.........

ZenMaster

For more on stem cells and cloning, go to CellNEWS at http://cellnews-blog.blogspot.com/